MannKind Corp (MNKD) stock
Close on Nov 12, 2026Market cap $1.34BP/E –Yield –
MannKind Corp grew revenue 31.7% to $413.37M over the twelve months to Sep 30, 2026. Operating income fell 116.3% to -$11.89M, moving the operating margin from 23.3% to -2.9%. Free cash flow was -$78.41M, down 280.7% from a year earlier. At the latest close the market valued the company at $1.34B.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $1.34B
- P/E ratio
- –
- Price to sales
- 3.24
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -5.86%
Fundamentals
- Revenue
- $413.37M
- Net income
- -$74.82M
- EPS, diluted
- -$0.23
- Free cash flow
- -$78.41M
- Book value per share
- -$0.12
- Diluted shares
- 320M
Trading
- Next earnings
- Feb 25, 2027 (estimated, before the open)
- Previous close
- $4.19
- Open
- $4.15
- Day's range
- $4.11 – $4.24
- Volume
- 3,505,029
- Average volume (20 days)
- 3,323,100
- Index membership
- Russell 2000, Russell 3000
- Beta (5 years)
- 1.07
- 52-week range
- $2.23 – $6.51
- RSI (14 days)
- 68.1
- Volatility (1 year)
- 70.3%
- Relative volume
- 0.82×
- WACC
- 10.3%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | MNKD | S&P 500 | Difference | MNKD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +32.9% | -2.7% | +35.6 pts | ||
| 3 months | +8.1% | -1.7% | +9.8 pts | ||
| Year to date | -26.6% | +11.9% | −38.5 pts | ||
| 1 year | -20.8% | +12.0% | −32.7 pts | ||
| 3 years | +21.3% | +78.2% | −56.9 pts | +6.6% | +21.2% |
| 5 years | -16.6% | +73.2% | −89.9 pts | -3.6% | +11.6% |
| 10 years | +26.1% | +309.6% | −283.6 pts | +2.3% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MannKind filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- News
- Results
- Results
- Results
About MannKind
Pharmaceutical Preparations
The company develops, manufactures, and commercializes therapeutic products and drug delivery systems for patient care. Its product portfolio includes Afrezza, Tyvaso DPI, V-Go, and Furoscix, alongside an on-body infusor technology and inhaled insulin formulations. In addition to commercial product sales, the enterprise provides contract manufacturing, development, and commercial supply services, and licenses its proprietary technologies. Its operations serve pharmaceutical and healthcare partners, with key collaborations and agreements involving United Therapeutics Corporation, Cipla, scPharmaceuticals, and Amphastar.
Company profile, executives and historyMannKind stock: common questions
What is MannKind's stock price?
MNKD closed at $4.16 on Nov 12, 2026, down 0.72% on the day. Over the past 52 weeks it traded between $2.23 and $6.51.
What is MannKind's market cap?
MannKind was worth $1.34B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is MNKD's P/E ratio?
MannKind lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.23), so it has no meaningful P/E ratio.
How much revenue does MannKind make?
MannKind reported revenue of $413.37M for the twelve months to Sep 30, 2026, up 31.7% from a year earlier.
Does MannKind pay a dividend?
No. MannKind has not paid a cash dividend over the last twelve months.
When does MannKind report earnings next?
MannKind is expected to report Q4 FY2026 results on Feb 25, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has MNKD stock performed over the past year?
Including dividends, MNKD returned -20.8% over the past year, against +12.0% for the S&P 500.
How many MNKD shares are sold short?
26M shares were sold short at the latest FINRA report, 8.37% of the float, or 10.3 days of average trading volume.
Who are MannKind's competitors?
Companies most similar to MannKind by business, industry and size include LQDA, XERS, IRWD, AMPH, OPK.
See a number that looks wrong?